Contact
Please use this form to send email to PR contact of this press release:
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
TO:
Please use this form to send email to PR contact of this press release:
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
TO: